Global Cancer Therapeutics Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The global cancer therapeutics market size was around $100.21 billion in 2018 and is expected to reach $197.45 billion by 2026, registering a CAGR of 13.4% through 2026.

The report offers comprehensive analyses of the industry dynamics, top investment pockets, key strategic developments, major market segments, and competitive landscape.

Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market growth.

However, high cost associated with oncology drug development along with adverse effects associated with cancer therapeutics are some of the factors that restrain the market growth. Conversely, the upsurge in demand for personalized medicine and high potential of developing nations is expected to provide new opportunities for the market players in future.

The global cancer therapeutics market trends are analyzed through the application vertical in the report. The lung cancer segment dominated the cancer therapeutics market, owing to the surge in prevalence of lung cancer and favorable government regulations toward lung cancer therapeutics.

The global cancer therapeutics market growth is also studied through the top selling drugs vertical in the report. The Revlimid segment occupied the largest share in the cancer therapeutics market in 2019, owing to the face that it received a breakthrough therapy designation. Revlimid (lenalidomide) belongs to the class of immunomodulatory drugs. It is an oral cancer drug indicated for multiple myeloma treatment. Revlimid functions against cancer cells partly by impacting the immune system. In October 2016, the combination therapy results of Revlimid and daratumumab (Johnson and Johnson) reported a surge in progression-free survival rate for patients suffering from refractory or relapsed multiple myeloma (or MM). This combination treatment was granted a breakthrough therapy designation by the FDA in July 2016.

Furthermore, the global cancer therapeutics market forecast is also analyzed through the region vertical. By region, North America is anticipated to occupy the largest share by 2026, owing to heavy funding by various organizations and increase in adoption of cancer therapeutics in this region. Moreover, rise in R&D investments is anticipated to facilitate the market growth during the forecast period

A rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA is expected to boost the market growth. Asia-Pacific is projected to witness significant growth in future, owing to increase in R&D investment and surge in cancer awareness. Furthermore, this region presents remarkable opportunities for the venture capitalists and investors, as the developed markets are comparatively saturated.

Increase in competition and continuous technological advancements have led to enhancements in the product portfolio; hence, product approvals and product development are one of the key developmental strategies adopted by the market players in the global cancer therapeutics market. For instance, in April 2018, the Swiss authority for the licensing and monitoring of therapeutic products (Swissmedic) granted approval for Roche's Alecensa (alectinib), as a first-line treatment for patients with advanced or metastatic ALK (anaplastic lymphoma kinase)-positive, non-small cell lung cancer (NSCLC).

Key market players

The major market players analyzed in the report include F. Hoffmann-La Roche AG, AbbVie, Inc., Celgene Corporation, Pfizer, Inc., Merck KGaA, Bristol-Myers Squibb Company, Johnson & Johnson, Astellas Pharma, Inc., Novartis AG, and Eli Lilly and Company.

The report analyzes and forecasts the cancer therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global cancer therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the cancer therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of cancer therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

Segmentation:

By Application
Blood Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Breast Cancer
Cervical Cancer
Head and Neck Cancer
Glioblastoma
Malignant Meningioma
Mesothelioma
Melanoma
Others

By Top Selling Drugs
Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Region
North America
Europe
LAMEA
Asia-Pacific

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

• To analyze and study the global cancer therapeutics capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
• Focuses on the key cancer therapeutics manufacturers, to study the capacity, production, value, market share and development plans in future.
• Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
• To define, describe and forecast the market by type, application and region.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.